# Chromium-Mediated Asymmetric Synthesis of Both Enantiomers of Acetoxytubipofuran

E. Peter Kündig,* Rita Cannas, Mundruppady Laxmisha, Liu Ronggang, and Sylvie Tchertchian

Department of Organic Chemistry, University of Geneva, 30 Quai Ernest Ansermet, 1211 Geneva 4, Switzerland

Received December 30, 2002; E-mail: peter.kundig@chiorg.unige.ch

Tricarbonylchromium-mediated dearomatization provides an efficient direct access to substituted cyclohexadienes.[1] Up to three C-substituents can be added in a regio- and stereoselective manner across an arene double bond in a one-pot sequence. We here report new aspects of this reaction in the context of an application to the asymmetric synthesis of both enantiomers of acetoxytubipofuran.

The furanoterpenes tubipofuran (**1**) and acetoxytubipofuran (**2**) were isolated from the Japanese stolonifer *Tubipora musica* Linnaeus in 1986 and were shown to be eudesmane-type marine furanosesquiterpenoids having a cis-fused decalin ring with a homoannular 1,3 diene system.[2] The compounds show ichtiotoxicity

1: R = CH$_3$
2: R = CH$_2$OAc

toward killifish (*Orizias latipes*), and 15-acetoxytubipofuran (**2**) shows cytotoxicity against B-16 melanoma cells in vitro (IC$_{50}$ 33 μg/mL). On the basis of the diene helicity rule, the 4a*S*,8a*R* absolute configuration was originally assigned to (+)-**1** but the work of Pedro and co-workers, who converted santonin into tubipofuran, showed that this has to be revised and that tubipofuran (+)-**1** has the 4a*R*,8a*S* absolute configuration as shown here.[3] A racemic synthesis of the tubipofurans was reported by Kanematsu and co-workers in 1994.[4]

Given the absence of an asymmetric synthesis of **2** and the synthetically interesting *cis*-fused cyclohexadiene with two adjacent stereogenic centers, one of them a quaternary one, we initiated a project of synthesis (Scheme 1). An aromatic precursor to the *cis*-fused ring system integrating a 1,3-cyclohexadiene would be an attractive route provided that the absolute configuration of the two stereogenic centers can be controlled. Retrosynthetically, formation of the furan ring in **2** via iodolacton **B** requires the decalin-acetic acid intermediate **A**. This in turn may be formed either via Pd-catalyzed allylic alkylation or via Claisen rearrangement from **6**, in turn obtained by reduction from **5**. In the forward direction, for the synthesis of cyclohexadiene enone **5** we require the addition of an acetaldehyde fragment to the ortho position of [(benzaldehyde)-Cr(CO)$_3$] (**3**) followed by a regioselective and diastereoselective acylation/alkylation at C(5).

In a preliminary study we established the feasibility of the transformation of benzaldehyde complex **3** into **5**. ortho-Addition of ethoxyvinyl Li[5] (**8**) to the imine complex **7a**,[6] followed by acylation/alkylation and imine hydrolysis gave **9** with the correct relative configuration (Scheme 2, eq 1).[7] Enol ether hydrolysis and intramolecular aldol condensation afforded **5** with the anticipated *cis*-decalin skeleton.

Scheme 1

Scheme 2

Scheme 3

For the synthesis of (4a*R*,8a*S*)-**5** we chose an enantioselective nucleophile addition of **8** to complex **7a** in the presence of the diether *S*,*S*-**10**. Enantiomeric excess values in the lower 90th percentiles had been obtained previously with this method when toluene was used as solvent.[8] The need for diethyl ether as solvent in the generation of **8** (bromide/lithium exchange) and this nucleophile's low thermal stability resulted in an erosion of both enantioselectivity and yield (Scheme 3). Fortunately, recrystallization of the fused diene−enone (4a*R*,8a*S*)-**5** afforded a highly enantioenriched product (>99% ee).

A rationale of observed enantioselectivity of nucleophilic addition is shown above, and preference of addition to the ortho, rather than

Scheme 4 [a]

[a] (a) NaBH₄, CeCl₃, MeOH, 98%; (b) NaH, PMBI, DMF, 88%; (c) ClCO₂Me, py, CH₂Cl₂, 95%; (d) 6 M NaOH, DMSO, 130 °C, 93%; (e) I₂, KI, NaHCO₃·H₂O/CH₂Cl₂: 94%; (f) Bu₃SnH, AIBN, tol, reflux, 91%; (g) 1. LDA/PhSeCl, 2. H₂O₂ 66%; (h) DDQ, 1.3 equiv, CH₂Cl₂/H₂O, 80%; (i) 1. DIBAL, tol, −40 °C 2. AcOH, 73%; (j) Ac₂O, py, DMAP, CH₂Cl₂, 92%.

to the ortho′ position is based on steric congestion state between a Ph group of the chiral ligand and the Cr(CO)₃ group in transition state **II**.

Reduction of (4a*R*,8a*S*)-**5** under Luche conditions afforded diol **11** as a single diastereoisomer with the hydride adding to the ketone from the less hindered, convex face of the molecule.[9] Selective protection of the primary alcohol as *p*-methoxybenzyl ether and conversion of the secondary alcohol into the carbonate **12** set the stage for the Pd-catalyzed allylic alkylation. The reaction with NaCMe(CO₂Me)₂ in the presence of Pd(dppe)₂ afforded regioselectively the product resulting from addition to C(7), and overall retention was the major pathway. The ratio of the diastereoisomers **13** at C(7) was 50:1. The transformation of **13** into acetoxytubipofuran **2** is depicted in Scheme 4, and details are given in the Supporting Information.

As mentioned above, the conversion of santonin into (+)-tubipofuran required a reassignment of the absolute configuration in the natural product.[3] Moreover, the observed $[\alpha]_D^{20}$ value was much larger (33) than that reported earlier (5.6), suggesting that the natural product isolated may not have been pure. A parallel situation exists for acetoxytubipofuran **2**. The natural product was assigned the *R,R*-configuration and its $[\alpha]_D^{20}$ value reported as +10.7 (*c* = 0.5, CHCl₃). Our measured value for (*R,R*) is −120 (*c* = 0.653, CHCl₃) and the CD spectrum showed a negative Cotton effect λ_{max} 274 (Δε −3), opposite to that reported (λ_{max} 270 (Δε +3)).[2a]

In parallel to the synthesis of (−)-**2**, we have developed a modified route to the natural product (+)-**2**. Condensation of the benzaldehyde complex **3** with D-valinol[10] followed by in situ methylation gave the chiral arylimine complex **7b** (Scheme 5). Diastereoselective nucleophilic addition/acylation/alkylation yielded (−)-(4a*S*,8a*R*)-**9**. Both the yield and the enantiomeric purity of the product were superior to the procedure used for the keto aldehyde (+)-(4a*R*,8a*S*)-**9**. Conversion of (+)-**9** by the same route as detailed before (Schemes 2 and 4) afforded (−)-**15**. The four-step sequence of formation of carbonate, Pd-catalyzed allylic substitution, hydrolysis/decarboxylation, and lactonization that was used in the synthesis of (*R,R*)-**2** was replaced now by the very efficient Eschenmoser−Claisen rearrangement−lactonization sequence[11,12] which afforded **14** as a 3:2 mixture of diastereoisomers. From here

Scheme 5 [a]

[a] (a) D-Valinol, Et₂O, rt; (b) NaH, MeI, THF, rt, 73% (a, b one pot); (c) **8**, THF, −78 °C; (d) HMPA, MeI, 5 bar CO, −78 °C to rt; (e) NaOEt, MeI, −78 °C to rt, 53% (c−e one pot); (f) HCl 2N, THF, 80 °C, 89%; (g) NaBH₄, CeCl₃, MeOH, 98%; (h) NaH, PMBI, DMF, 88%; (i) I₂, THF, H₂O, 73%.

on the synthesis followed that shown in Scheme 4. (*S,S*)-Tubipofuran ((*S,S*)-**2**) showed a $[\alpha]_D^{20}$ of +100.3 (*c* = 0.29, CHCl₃).

In summary, this Communication reports new asymmetric methodology of Cr(CO)₃-mediated dearomatization and its application to the synthesis of (+)- and (−)-acetoxytubipofuran. Chiroptical data show that a revision of the assigned structure of the natural product is required.

Supporting Information Available: Experimental procedures and physical data of all compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

References

(1) Pape, A.; Kaliappan, K.; Kündig, E. P. *Chem. Rev.* **2000**, *100*, 2917−2940.
(2) (a) Iguchi, K.; Mori, K.; Suzuki, M.; Takahashi, H.; Yamada, Y. *Chem. Lett.* **1986**, 1789. (b) Brieskorn, K. H.; Noble, P. *Phytochemistry* **1983**, *22*, 187.
(3) Blay, G.; Cardona, L.; Garcia, B.; Pedro, J.; Sanchez, J. J. *J. Org. Chem.* **1996**, *61*, 3815.
(4) Ojida, A.; Tanoue, F.; Kanematsu, K. *J. Org. Chem.* **1994**, *59*, 5970−5976.
(5) Wollenberg, R. H.; Albizati, K. F.; Peries, R. *J. Am. Chem. Soc.* **1977**, *99*, 7365−7367.
(6) Kündig, E. P.; Ripa, A.; Liu, R. G.; Amurrio, D.; Bernardinelli, G. *Organometallics* **1993**, *12*, 3724−3737.
(7) Kündig, E. P.; Ripa, A.; Liu, R. G.; Bernardinelli, G. *J. Org. Chem.* **1994**, *59*, 4773−4783.
(8) Amurrio, D.; Khan, K.; Kündig, E. P. *J. Org. Chem.* **1996**, *61*, 2258−2259.
(9) Gemal, A. L.; Luche, J.-L. *J. Am. Chem. Soc.* **1981**, *103*, 5454−5459.
(10) (a) Meyers, A. I.; McKennon, M. J.; Drauz, K.; Schwarm, M. *J. Org. Chem.* **1993**, *58*, 3568−3571. (b) Meyers, A. I. *Tetrahedron* **1992**, *48*, 2589−2612. (c) Devine, P. N.; Reilly, M.; Oh, T. *Tetrahedron Lett.* **1993**, *34*, 5827−5830. (d) Betz, J.; Heuschmann, M. *Tetrahedron Lett.* **1995**, *36*, 4043. (e) Meyers, A. I.; Matulenko, M. A. *J. Org. Chem.* **1996**, *61*, 573−580. (f) Negoro, N.; Yanada, R.; Okaniwa, M.; Yanada, K.; Fujita T. *Synlett* **1998**, 835−836. (g) Yanada, R.; Negoro, N.; Okaniwa, M.; Miwa, Y.; Taga, T.; Yanada, K.; Fujita, T. *Synlett* **1999**, 537−540.
(11) (a) Wick, A. E.; Felix, D.; Steen, K.; Eschenmoser, A. *Helv. Chim. Acta* **1964**, *47*, 2425−2430. (b) Chen, C.-Y.; Hart, D. J. *J. Org. Chem.* **1993**, *58*, 3840−3849.(c) Amano, S.; Takemura, N.; Ohtsuka, M.; Ogawa, S.; Chida, N. *Tetrahedron* **1999**, *55*, 3855−3870.
(12) Feugeas, P. C.; Olschwang, D. *Bull. Soc. Chim. Fr.* **1968**, 4985−4990.

JA029957N